{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:41:47Z","timestamp":1789771307873,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2022C03G2013730"],"award-info":[{"award-number":["2022C03G2013730"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2020YFA0113003"],"award-info":[{"award-number":["2020YFA0113003"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2022ZFJH003"],"award-info":[{"award-number":["2022ZFJH003"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jconrel.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:31:34Z","timestamp":1723462294000},"page":"112-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["ROS-responsive\u00a0nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis"],"prefix":"10.1016","volume":"374","author":[{"given":"Qigu","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiduo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingduo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyou","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongcui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jconrel.2024.08.006_bb0005","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.jconrel.2024.08.006_bb0010","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.cgh.2023.04.004","article-title":"Recent advances in the Management of Primary Sclerosing Cholangitis","volume":"21","author":"Assis","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.006_bb0020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jhbp.194","article-title":"Clinical profiles of patients with primary sclerosing cholangitis in the elderly","volume":"22","author":"Tanaka","year":"2015","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.006_bb0025","first-page":"312","article-title":"Primary sclerosing cholangitis in Turkish patients: characteristic features and prognosis","volume":"8","author":"Ataseven","year":"2009","journal-title":"Hepatobil. Pancreat. Dis. Int.: HBPD INT"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.jconrel.2024.08.006_bb0035","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jhep.2022.10.007","article-title":"Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases\u2020","volume":"78","author":"Nevens","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0040","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7","key":"10.1016\/j.jconrel.2024.08.006_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of Obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2024.08.006_bb0050","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.jconrel.2024.08.006_bb0055","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.jconrel.2024.08.006_bb0065","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.14309\/ajg.0000000000001956","article-title":"A randomized, dose-finding, proof-of-concept study of Berberine Ursodeoxycholate in patients with primary Sclerosing cholangitis","volume":"117","author":"Kowdley","year":"2022","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.08.006_bb0070","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cts.12421","article-title":"Modeling and experimental studies of Obeticholic acid exposure and the impact of cirrhosis stage","volume":"9","author":"Edwards","year":"2016","journal-title":"Clin. Transl. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2024.08.006_bb0075","article-title":"Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis","volume":"1865","author":"Carino","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.jconrel.2024.08.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120882","article-title":"Obeticholic acid aggravates liver injury by up-regulating the liver expression of osteopontin in obstructive cholestasis","volume":"307","author":"Wang","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0085","article-title":"Obeticholic acid induces Hepatoxicity via FXR in the NAFLD mice","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.08.006_bb0090","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00204-022-03266-6","article-title":"Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR\/SHP pathway","volume":"96","author":"Zhang","year":"2022","journal-title":"Arch. Toxicol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.08.006_bb0095","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/hep.31545","article-title":"The Apelin-Apelin receptor Axis triggers Cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jconrel.2024.08.006_bb0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2015.05.003","article-title":"New trends in guided nanotherapies for digestive cancers: a systematic review","volume":"209","author":"Fernandes","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.08.006_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102582","article-title":"Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice","volume":"59","author":"Zhuge","year":"2023","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.006_bb0110","article-title":"Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury","volume":"3","author":"Iruzubieta","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jconrel.2024.08.006_bb0120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.actbio.2022.06.024","article-title":"ROS-responsive polymer nanoparticles with enhanced loading of dexamethasone effectively modulate the lung injury microenvironment","volume":"148","author":"Muhammad","year":"2022","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.jconrel.2024.08.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202302940","article-title":"A sequential dual functional supramolecular hydrogel with promoted drug release to scavenge ROS and stabilize HIF-1\u03b1 for myocardial infarction treatment","volume":"13","author":"Wang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0130","first-page":"550","article-title":"A reactive oxygen species-responsive hydrogel encapsulated with bone marrow derived stem cells promotes repair and regeneration of spinal cord injury","volume":"19","author":"Li","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102569","article-title":"Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress","volume":"59","author":"Abulikemu","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0140","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.2147\/IJN.S208938","article-title":"Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy","volume":"14","author":"Pandya","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.08.006_bb0145","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.redox.2018.07.002","article-title":"Polydatin prevents fructose-induced liver inflammation and lipid deposition through increasing miR-200a to regulate Keap1\/Nrf2 pathway","volume":"18","author":"Zhao","year":"2018","journal-title":"Redox Biol."},{"issue":"12","key":"10.1016\/j.jconrel.2024.08.006_bb0150","article-title":"Vesicular antibodies: shedding light on antibody therapeutics with cell membrane nanotechnology","volume":"35","author":"Zhao","year":"2023","journal-title":"Adv. Mater. (Deerfield Beach, Fla)"},{"key":"10.1016\/j.jconrel.2024.08.006_bb0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ebiom.2019.06.047","article-title":"Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells","volume":"45","author":"Segaliny","year":"2019","journal-title":"EBioMedicine"},{"issue":"18","key":"10.1016\/j.jconrel.2024.08.006_bb0160","article-title":"Genetically engineering cell membrane-coated BTO nanoparticles for MMP2-activated piezocatalysis-immunotherapy","volume":"35","author":"Tang","year":"2023","journal-title":"Adv. Mater. (Deerfield Beach, Fla)"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0165","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1038\/s41467-023-41609-8","article-title":"Nongenetic surface engineering of mesenchymal stromal cells with polyvalent antibodies to enhance targeting efficiency","volume":"14","author":"Ye","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2018.06.012","article-title":"Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: so near and yet so far","volume":"132","author":"Thanuja","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0175","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2015.05.007","article-title":"Synergistic effects of co-administration of suicide gene expressing mesenchymal stem cells and prodrug-encapsulated liposome on aggressive lung melanoma metastases in mice","volume":"209","author":"Zhang","year":"2015","journal-title":"J. Controll. Rel.: Off. J. Controll. Rel. Soc."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0180","doi-asserted-by":"crossref","first-page":"1111963","DOI":"10.3389\/fbioe.2023.1111963","article-title":"Membrane-camouflaged biomimetic nanoparticles as potential immunomodulatory solutions for sepsis: an overview","volume":"11","author":"Wang","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1741-7015-10-56","article-title":"Therapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure","volume":"10","author":"Cao","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0190","first-page":"430","article-title":"Dexamethasone-loaded ROS-responsive poly(thioketal) nanoparticles suppress inflammation and oxidative stress of acute lung injury","volume":"14","author":"Zhai","year":"2022","journal-title":"Bioact. Mater."},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.006_bb0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41419-022-04708-w","article-title":"Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabilization of SLC7A11 in acute liver injury","volume":"13","author":"Lin","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jconrel.2021.05.031","article-title":"Active stealth and self-positioning biomimetic vehicles achieved effective antitumor therapy","volume":"335","author":"Li","year":"2021","journal-title":"J. Controll. Rel.: Off. J. Controll. Rel. Soc."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0205","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-022-01194-6","article-title":"Applications of human organoids in the personalized treatment for digestive diseases","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2024.08.006_bb0210","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41574-022-00733-z","article-title":"Modelling metabolic diseases and drug response using stem cells and organoids","volume":"18","author":"Hu","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.006_bb0215","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","article-title":"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis","volume":"9","author":"Zhou","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.jconrel.2024.08.006_bb0220","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1002\/ptr.7055","article-title":"Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice","volume":"35","author":"Li","year":"2021","journal-title":"Phytother. Res.: PTR"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0225","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.apsb.2022.06.010","article-title":"Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubin","volume":"13","author":"Hong","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0230","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2024.08.006_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1081553","article-title":"Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob\/ob mice","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"18","key":"10.1016\/j.jconrel.2024.08.006_bb0240","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1016\/j.cell.2022.07.025","article-title":"Sublethal cytochrome c release generates drug-tolerant persister cells","volume":"185","author":"Kalkavan","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.006_bb0245","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0250","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.jconrel.2024.08.006_bb0255","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.jconrel.2024.08.006_bb0260","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/hep.26160","article-title":"Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells","volume":"57","author":"Anth\u00e9rieu","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.006_bb0265","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/jhep.2001.22702","article-title":"Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition","volume":"33","author":"Yerushalmi","year":"2001","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jconrel.2024.08.006_bb0270","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","article-title":"Reactive oxygen species, cellular redox systems, and apoptosis","volume":"48","author":"Circu","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0275","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev.biochem.73.011303.073706","article-title":"Cytochrome C-mediated apoptosis","volume":"73","author":"Jiang","year":"2004","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tibs.2018.11.002","article-title":"The structural basis of Necroptotic cell death signaling","volume":"44","author":"Petrie","year":"2019","journal-title":"Trends Biochem. Sci."},{"issue":"37","key":"10.1016\/j.jconrel.2024.08.006_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202001588","article-title":"New insights into biocompatible Iron oxide nanoparticles: a potential booster of gene delivery to stem cells","volume":"16","author":"Zhang","year":"2020","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0290","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12967-023-04028-3","article-title":"Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration","volume":"21","author":"Hu","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0295","doi-asserted-by":"crossref","DOI":"10.1177\/2040622321993442","article-title":"Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges","volume":"12","author":"He","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0300","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41392-022-01024-9","article-title":"Human organoids in basic research and clinical applications","volume":"7","author":"Tang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2024.08.006_bb0305","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.039347","article-title":"Disease modelling in human organoids","volume":"12","author":"Lancaster","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0310","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-pathmechdis-012419-032611","article-title":"Human organoids: tools for understanding biology and treating diseases","volume":"15","author":"Schutgens","year":"2020","journal-title":"Annu. Rev. Pathol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.006_bb0315","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.30470","article-title":"Bile-derived organoids from patients with primary Sclerosing cholangitis recapitulate their inflammatory immune profile","volume":"70","author":"Soroka","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0320","article-title":"MSC-derived exosomes attenuate hepatic fibrosis in primary sclerosing cholangitis through inhibition of Th17 differentiation","volume":"19","author":"Chen","year":"2024","journal-title":"Asian J. Pharma. Sci."},{"key":"10.1016\/j.jconrel.2024.08.006_bb0325","first-page":"0207","article-title":"Human placental mesenchymal stem cells relieve primary Sclerosing cholangitis via upregulation of TGR5 in Mdr2\u2212\/\u2212 mice and human intrahepatic Cholangiocyte organoid models","volume":"6","author":"Yao","year":"2023","journal-title":"Research (Washington, DC)"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.006_bb0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13287-021-02271-3","article-title":"Human placenta mesenchymal stem cell-derived exosomes delay H2O2-induced aging in mouse cholangioids","volume":"12","author":"Chen","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"10.1016\/j.jconrel.2024.08.006_bb0335","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jhep.2012.11.033","article-title":"PDX-1\/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: possible implications for sclerosing cholangitis","volume":"58","author":"Marzioni","year":"2013","journal-title":"J. Hepatol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:43:57Z","timestamp":1741257837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924005455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":67,"alternative-id":["S0168365924005455"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.006","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ROS-responsive\u00a0nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}